Nanomedicine-Based Neuroprotective Strategies in Patient Specific-iPSC and Personalized Medicine

In recent decades, nanotechnology has attracted major interests in view of drug delivery systems and therapies against diseases, such as cancer, neurodegenerative diseases, and many others. Nanotechnology provides the opportunity for nanoscale particles or molecules (so called “Nanomedicine”) to be delivered to the targeted sites, thereby, reducing toxicity (or side effects) and improving drug bioavailability. Nowadays, a great deal of nano-structured particles/vehicles has been discovered, including polymeric nanoparticles, lipid-based nanoparticles, and mesoporous silica nanoparticles. Nanomedical utilizations have already been well developed in many different aspects, including disease treatment, diagnostic, medical devices designing, and visualization (i.e., cell trafficking). However, while quite a few successful progressions on chemotherapy using nanotechnology have been developed, the implementations of nanoparticles on stem cell research are still sparsely populated. Stem cell applications and therapies are being considered to offer an outstanding potential in the treatment for numbers of maladies. Human induced pluripotent stem cells (iPSCs) are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state. Although the exact mechanisms underlying are still unclear, iPSCs are already being considered as useful tools for drug development/screening and modeling of diseases. Recently, personalized medicines have drawn great attentions in biological and pharmaceutical studies. Generally speaking, personalized medicine is a therapeutic model that offers a customized healthcare/cure being tailored to a specific patient based on his own genetic information. Consequently, the combination of nanomedicine and iPSCs could actually be the potent arms for remedies in transplantation medicine and personalized medicine. This review will focus on current use of nanoparticles on therapeutical applications, nanomedicine-based neuroprotective manipulations in patient specific-iPSCs and personalized medicine.

[1]  T. Robbins,et al.  The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. , 2004, Brain : a journal of neurology.

[2]  George Q. Daley,et al.  Reprogramming of human somatic cells to pluripotency with defined factors , 2008, Nature.

[3]  J. Cryan,et al.  Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution. , 2013, Journal of pharmaceutical sciences.

[4]  Y. Yoon,et al.  Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. , 2013, Biomaterials.

[5]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[6]  F. Alexis Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)] , 2005 .

[7]  Rainer H Müller,et al.  Lipid nanoparticles for parenteral delivery of actives. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  Silvia Licoccia,et al.  Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. , 2012, ACS nano.

[9]  A. Giordano,et al.  Neuroprotective effects of PrxI over‐expression in an in vitro human Alzheimer's disease model , 2013, Journal of cellular biochemistry.

[10]  Kwideok Park,et al.  Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[12]  C. Peschle,et al.  Identification of the hemangioblast in postnatal life. , 2002 .

[13]  H. Harashima,et al.  The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. , 2013, Biological & pharmaceutical bulletin.

[14]  T. Ichisaka,et al.  Generation of germline-competent induced pluripotent stem cells , 2007, Nature.

[15]  Krishanu Saha,et al.  Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.

[16]  P. Maincent,et al.  Nanoparticle strategies for the oral delivery of insulin , 2008, Expert opinion on drug delivery.

[17]  B. Sarmento,et al.  Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles , 2007, International journal of nanomedicine.

[18]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[19]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[20]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[21]  A. Herrmann,et al.  Drug delivery systems based on nucleic acid nanostructures. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Yao Sun Myocardial repair/remodelling following infarction: roles of local factors. , 2008, Cardiovascular research.

[23]  H. Deng,et al.  Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds , 2013, Science.

[24]  Susan Lindquist,et al.  Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.

[25]  R. Kumar,et al.  Reduction in the Initial-Burst Release by Surface Crosslinking of PLGA Microparticles Containing Hydrophilic or Hydrophobic Drugs , 2005, Drug development and industrial pharmacy.

[26]  C. Venkataraman,et al.  Size distribution and dye release properties of submicron liposome aerosols , 2013 .

[27]  T. Dawson Unraveling the role of defective genes in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[28]  P. Knoepfler,et al.  Inducing iPSCs to escape the dish. , 2011, Cell stem cell.

[29]  M. Kaufman,et al.  Establishment in culture of pluripotential cells from mouse embryos , 1981, Nature.

[30]  J. Penney,et al.  Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.

[31]  R. Müller,et al.  Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[32]  Amit Kumar,et al.  Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Jiangnan Yu,et al.  Non‐Viral Co‐Delivery of the Four Yamanaka Factors for Generation of Human Induced Pluripotent Stem Cells via Calcium Phosphate Nanocomposite Particles , 2013 .

[34]  Li-Li Zuo,et al.  The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. , 2013, Gene.

[35]  S. Chiou,et al.  Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. , 2013, ACS nano.

[36]  Gann Ting,et al.  Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs , 2013, PloS one.

[37]  S. Goldman Stem and progenitor cell–based therapy of the human central nervous system , 2005, Nature Biotechnology.

[38]  Balaji Narasimhan,et al.  Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Christopher G Thanos,et al.  Targeted nanoparticle-based drug delivery and diagnosis , 2007, Journal of drug targeting.

[40]  C. Brunstein Umbilical cord blood transplantation for the treatment of hematologic malignancies. , 2011, Cancer control : journal of the Moffitt Cancer Center.

[41]  G. Ming,et al.  Glial influences on neural stem cell development: cellular niches for adult neurogenesis , 2005, Current Opinion in Neurobiology.

[42]  A. Kakita,et al.  Relationship Among &agr;-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra , 2006, Journal of neuropathology and experimental neurology.

[43]  Yan Zhang,et al.  Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. , 2012, Biomaterials.

[44]  Hongjun Song,et al.  Adult neural stem cells in the mammalian central nervous system , 2009, Cell Research.

[45]  K. Sen,et al.  Second generation liposomal cancer therapeutics: transition from laboratory to clinic. , 2013, International journal of pharmaceutics.

[46]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[47]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[48]  Daniel T. Montoro,et al.  Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells , 2010, PLoS currents.

[49]  A. Álvarez-Buylla,et al.  For the Long Run Maintaining Germinal Niches in the Adult Brain , 2004, Neuron.

[50]  B Ruozi,et al.  PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.

[51]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[52]  D. P. O'Neal,et al.  Simulation of transport and extravasation of nanoparticles in tumors which exhibit enhanced permeability and retention effect , 2013, Comput. Methods Programs Biomed..

[53]  V. Préat,et al.  PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[54]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[55]  M. MacDonald,et al.  Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.

[56]  P. Conti,et al.  Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. , 2013, Biomaterials.

[57]  Jeffrey T. Leek,et al.  Personalized medicine: Keep a way open for tailored treatments , 2012, Nature.

[58]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[59]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[60]  Vinit Kumar,et al.  Fluorescent carbon nanoparticles in medicine for cancer therapy. , 2013, ACS medicinal chemistry letters.

[61]  G. Martin,et al.  Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Jun Liu,et al.  Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.

[63]  M. McLaren Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells. Relationship to cell morphology. , 1996, Investigative ophthalmology & visual science.

[64]  Y. Sasai,et al.  In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction , 2009, Journal of Cell Science.

[65]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[66]  Kwangmeyung Kim,et al.  Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. , 2014, Carbohydrate polymers.

[67]  Krishanu Saha,et al.  Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues , 2010, Cell.

[68]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[69]  A. Vortmeyer,et al.  Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. , 2006, Cancer research.

[70]  Jane S. Paulsen,et al.  CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[71]  C. von Kalle,et al.  Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. , 2004, Seminars in hematology.

[72]  G. P. Agrawal,et al.  Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir , 2013, Drug development and industrial pharmacy.

[73]  Li Xue,et al.  The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained-release carriers: a PLGA particle system. , 2013, Journal of pharmaceutical sciences.

[74]  A. Giordano,et al.  A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening , 2014, Journal of cellular physiology.

[75]  D. Chirio,et al.  Preparation of solid lipid nanoparticles from W/O/W emulsions: Preliminary studies on insulin encapsulation , 2009, Journal of microencapsulation.

[76]  Huck-Hui Ng,et al.  Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. , 2009, Cell stem cell.

[77]  C. Svendsen,et al.  Induced pluripotent stem cells: a new revolution for clinical neurology? , 2011, The Lancet Neurology.

[78]  Sudesh Kumar Yadav,et al.  Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.

[79]  T. Shimazaki,et al.  [Mammalian neural stem cells]. , 2008, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[80]  G. Fishman,et al.  iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration. , 2013, Human molecular genetics.

[81]  Diane J. Burgess,et al.  Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[82]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[83]  T. Gillis,et al.  Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. , 2012, Cell stem cell.

[84]  M. Ang,et al.  Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye , 2012, International journal of nanomedicine.

[85]  Kristopher L. Nazor,et al.  Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.

[86]  Ji Young Kim,et al.  Robust Enhancement of Neural Differentiation from Human ES and iPS Cells Regardless of their Innate Difference in Differentiation Propensity , 2010, Stem Cell Reviews and Reports.

[87]  H. Sugiyama,et al.  A synthetic small molecule for rapid induction of multiple pluripotency genes in mouse embryonic fibroblasts , 2012, Scientific Reports.

[88]  T. Mikkelsen,et al.  Dissecting direct reprogramming through integrative genomic analysis , 2008, Nature.

[89]  S. Finkbeiner,et al.  Modeling Huntington's disease with induced pluripotent stem cells , 2013, Molecular and Cellular Neuroscience.

[90]  C. Cho,et al.  Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. , 2005, Cancer biotherapy & radiopharmaceuticals.

[91]  S. Prabhu,et al.  Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. , 2005, International journal of pharmaceutics.

[92]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[93]  Shinya Yamanaka,et al.  Immunogenicity of induced pluripotent stem cells. , 2011, Circulation research.

[94]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[95]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[96]  Lie-Chwen Lin,et al.  Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. , 2011, Food chemistry.

[97]  K. Hochedlinger,et al.  Induced pluripotency: history, mechanisms, and applications. , 2010, Genes & development.

[98]  Yoshimasa Tanaka,et al.  Clinical grade iPS cells: need for versatile small molecules and optimal cell sources. , 2013, Chemistry & biology.

[99]  S. Laurent,et al.  Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. , 2013, International journal of pharmaceutics.

[100]  M. Adomako,et al.  Oral DNA vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), against infectious haematopoietic necrosis virus using PLGA [Poly(D,L-Lactic-Co-Glycolic Acid)] nanoparticles. , 2012, Journal of fish diseases.

[101]  A. Almeida,et al.  Solid lipid nanoparticles as a drug delivery system for peptides and proteins. , 2007, Advanced drug delivery reviews.

[102]  R. Ferrante,et al.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials. , 2009, Biochimica et biophysica acta.